2026 Q2 - tulosraportti
37 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 81 | - | - | ||
| 900 | - | - | ||
| 2 000 | - | - | ||
| 5 979 | - | - | ||
| 500 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·4 t sittenVery interesting reading: I asked ChatGPT Is there a possibility that the Circio technology can solve the riddle of cancer Calling it a definitive solution to "the riddle of cancer" is too early, but the Norwegian biotech company Circio Holding ASA (formerly Targovax) is holding a very promising piece that can revolutionize parts of cancer treatment. Their primary weapon is circular RNA (circRNA) and the circVec platform. While traditional mRNA (like the one we know from the COVID-19 vaccines) is quickly degraded in the body, circular RNA is shaped like a closed ring. This makes it extremely stable. Circio is trying to solve the cancer riddle via three tracks: 1. Next generation of "in vivo" CAR-T cell therapy This is the most exciting area in 2026. Traditional CAR-T therapy requires taking immune cells out of the patient, reprogramming them in a laboratory, and injecting them back in – an extremely expensive and complicated process. • The solution: Circio has entered into major partnerships with, among others, Acuitas Therapeutics and Full Circles Therapeutics. The goal is to inject the technology directly into the patient (in vivo), where the circular RNA reprograms the body's own T cells to hunt cancer cells. • The advantage: Because Circio's circVec technology delivers up to 50 times longer-lasting protein expression than normal mRNA, it can keep immune cells "battle-ready" against the cancer for a much longer time without constant retreatment. 2. Cancer vaccines against aggressive cancers Circio has developed a therapeutic cancer vaccine called TG01. It targets specifically RAS-mutated cancers, which cover some of the most lethal and hardest-to-treat cancer types, including pancreatic cancer and lung cancer. TG01 is tested in clinical trials in combination with other immunotherapy to train the immune system to recognize and attack mutated cancer cells. 3. Oncolytic viruses (cancer-eating viruses) Through their ONCOS-102 program, they are developing modified adenoviruses designed toC infect and burst solid cancer tumors from the inside, while activating the body's own immune system against the rest of the cancer cells. The challenge: Can it "solve the riddle"? Cancer is not one disease, but over 200 different diagnoses. Circio does not solve the entire riddle alone, but their technology can become the key to making immunotherapy far more effective, cheaper, and accessible to the masses. The company raised significant funds in 2026 (approx. 620 million NOK) precisely to move their preclinical RNA platforms closer to real patient trials. If you are interested, I can dive deeper into: • How clinical trials (phase 1 and 2) are progressing for the cancer vaccine TG01. • Why circular RNA is predicted to take over the market from traditional mRNA in the medicine of the future. So buckle up and sit on your hands while the robots and day traders play with the stocks.
That was what the priest said to me when I had constipation, you must never stop believing..- 10 t sittenWill the downturn on wall street put pressure on circio do you think? I don't know how it works with knock on effects etc but I wonder if there will be more turbulence tomorrow because of it? Like we had at the end of today.. Or is there no correlation?
Would perhaps be more relevant if there actually was a downturn on wall street. Nasdaq +.022 s&p500 -0.22. Don't quite see what you are talking about 
·12 t sittenRecovering now in the closing auction 😃
Good with patience. What happens to the share price today and tomorrow doesn't matter at all. Rome wasn't built in a day, say those who remember the longest, and no, not rum in a bottle, or room for Romerike (Akershus) 😉
·12 t sittenHULTEN shared this earlier, think it needs a bit of top placement now after some people are finished with work! LinkedIn copy Benjamin McLeod ( . Following Founder @ Convey Bio | Co-Host of The Biotech Voyager This is one of the hottest early-stage companies so far this year. The company is Circio Holding ASA They've built a gene expression system that uses circular RNA biogenesis It's seriously impressive: - RNA that last 75x longer than normal - significant reduction in immune response over standard gene delivery highly potent, to the extent that an eye delivery resulted in a 10x response with ONE-TENTH OF THE DOSE Seriously impressive run this year Many thanks to Victor Levitsky for a short overview We barely scratched the surface on all the cool data they've generated Anything else you'd add? Drop it in the comments. https://www.linkedin.com/posts/benjamin-mcleod_this-is-one-of-the-hottest-early-stage-companies-ugcPost-7513474825743437824-HyJM/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7513557495605374976&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUSkreiv dette til han Nice one Benjamin Circio has actually put together a pretty solid data package this year - expression advantage now shown in heart, eye and CNS, first therapeutic gene data, and long durability on the non-viral CAR-T side. Worth a closer look if you haven't dug into the full 2026 progress yet. Fikk svar Definitely need to read deeper Då får vi se om han kommer me noe senere
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
37 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenVery interesting reading: I asked ChatGPT Is there a possibility that the Circio technology can solve the riddle of cancer Calling it a definitive solution to "the riddle of cancer" is too early, but the Norwegian biotech company Circio Holding ASA (formerly Targovax) is holding a very promising piece that can revolutionize parts of cancer treatment. Their primary weapon is circular RNA (circRNA) and the circVec platform. While traditional mRNA (like the one we know from the COVID-19 vaccines) is quickly degraded in the body, circular RNA is shaped like a closed ring. This makes it extremely stable. Circio is trying to solve the cancer riddle via three tracks: 1. Next generation of "in vivo" CAR-T cell therapy This is the most exciting area in 2026. Traditional CAR-T therapy requires taking immune cells out of the patient, reprogramming them in a laboratory, and injecting them back in – an extremely expensive and complicated process. • The solution: Circio has entered into major partnerships with, among others, Acuitas Therapeutics and Full Circles Therapeutics. The goal is to inject the technology directly into the patient (in vivo), where the circular RNA reprograms the body's own T cells to hunt cancer cells. • The advantage: Because Circio's circVec technology delivers up to 50 times longer-lasting protein expression than normal mRNA, it can keep immune cells "battle-ready" against the cancer for a much longer time without constant retreatment. 2. Cancer vaccines against aggressive cancers Circio has developed a therapeutic cancer vaccine called TG01. It targets specifically RAS-mutated cancers, which cover some of the most lethal and hardest-to-treat cancer types, including pancreatic cancer and lung cancer. TG01 is tested in clinical trials in combination with other immunotherapy to train the immune system to recognize and attack mutated cancer cells. 3. Oncolytic viruses (cancer-eating viruses) Through their ONCOS-102 program, they are developing modified adenoviruses designed toC infect and burst solid cancer tumors from the inside, while activating the body's own immune system against the rest of the cancer cells. The challenge: Can it "solve the riddle"? Cancer is not one disease, but over 200 different diagnoses. Circio does not solve the entire riddle alone, but their technology can become the key to making immunotherapy far more effective, cheaper, and accessible to the masses. The company raised significant funds in 2026 (approx. 620 million NOK) precisely to move their preclinical RNA platforms closer to real patient trials. If you are interested, I can dive deeper into: • How clinical trials (phase 1 and 2) are progressing for the cancer vaccine TG01. • Why circular RNA is predicted to take over the market from traditional mRNA in the medicine of the future. So buckle up and sit on your hands while the robots and day traders play with the stocks.That was what the priest said to me when I had constipation, you must never stop believing..
- 10 t sittenWill the downturn on wall street put pressure on circio do you think? I don't know how it works with knock on effects etc but I wonder if there will be more turbulence tomorrow because of it? Like we had at the end of today.. Or is there no correlation?Would perhaps be more relevant if there actually was a downturn on wall street. Nasdaq +.022 s&p500 -0.22. Don't quite see what you are talking about
- ·12 t sittenRecovering now in the closing auction 😃Good with patience. What happens to the share price today and tomorrow doesn't matter at all. Rome wasn't built in a day, say those who remember the longest, and no, not rum in a bottle, or room for Romerike (Akershus) 😉
- ·12 t sittenHULTEN shared this earlier, think it needs a bit of top placement now after some people are finished with work! LinkedIn copy Benjamin McLeod ( . Following Founder @ Convey Bio | Co-Host of The Biotech Voyager This is one of the hottest early-stage companies so far this year. The company is Circio Holding ASA They've built a gene expression system that uses circular RNA biogenesis It's seriously impressive: - RNA that last 75x longer than normal - significant reduction in immune response over standard gene delivery highly potent, to the extent that an eye delivery resulted in a 10x response with ONE-TENTH OF THE DOSE Seriously impressive run this year Many thanks to Victor Levitsky for a short overview We barely scratched the surface on all the cool data they've generated Anything else you'd add? Drop it in the comments. https://www.linkedin.com/posts/benjamin-mcleod_this-is-one-of-the-hottest-early-stage-companies-ugcPost-7513474825743437824-HyJM/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7513557495605374976&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUSkreiv dette til han Nice one Benjamin Circio has actually put together a pretty solid data package this year - expression advantage now shown in heart, eye and CNS, first therapeutic gene data, and long durability on the non-viral CAR-T side. Worth a closer look if you haven't dug into the full 2026 progress yet. Fikk svar Definitely need to read deeper Då får vi se om han kommer me noe senere
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 81 | - | - | ||
| 900 | - | - | ||
| 2 000 | - | - | ||
| 5 979 | - | - | ||
| 500 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
37 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenVery interesting reading: I asked ChatGPT Is there a possibility that the Circio technology can solve the riddle of cancer Calling it a definitive solution to "the riddle of cancer" is too early, but the Norwegian biotech company Circio Holding ASA (formerly Targovax) is holding a very promising piece that can revolutionize parts of cancer treatment. Their primary weapon is circular RNA (circRNA) and the circVec platform. While traditional mRNA (like the one we know from the COVID-19 vaccines) is quickly degraded in the body, circular RNA is shaped like a closed ring. This makes it extremely stable. Circio is trying to solve the cancer riddle via three tracks: 1. Next generation of "in vivo" CAR-T cell therapy This is the most exciting area in 2026. Traditional CAR-T therapy requires taking immune cells out of the patient, reprogramming them in a laboratory, and injecting them back in – an extremely expensive and complicated process. • The solution: Circio has entered into major partnerships with, among others, Acuitas Therapeutics and Full Circles Therapeutics. The goal is to inject the technology directly into the patient (in vivo), where the circular RNA reprograms the body's own T cells to hunt cancer cells. • The advantage: Because Circio's circVec technology delivers up to 50 times longer-lasting protein expression than normal mRNA, it can keep immune cells "battle-ready" against the cancer for a much longer time without constant retreatment. 2. Cancer vaccines against aggressive cancers Circio has developed a therapeutic cancer vaccine called TG01. It targets specifically RAS-mutated cancers, which cover some of the most lethal and hardest-to-treat cancer types, including pancreatic cancer and lung cancer. TG01 is tested in clinical trials in combination with other immunotherapy to train the immune system to recognize and attack mutated cancer cells. 3. Oncolytic viruses (cancer-eating viruses) Through their ONCOS-102 program, they are developing modified adenoviruses designed toC infect and burst solid cancer tumors from the inside, while activating the body's own immune system against the rest of the cancer cells. The challenge: Can it "solve the riddle"? Cancer is not one disease, but over 200 different diagnoses. Circio does not solve the entire riddle alone, but their technology can become the key to making immunotherapy far more effective, cheaper, and accessible to the masses. The company raised significant funds in 2026 (approx. 620 million NOK) precisely to move their preclinical RNA platforms closer to real patient trials. If you are interested, I can dive deeper into: • How clinical trials (phase 1 and 2) are progressing for the cancer vaccine TG01. • Why circular RNA is predicted to take over the market from traditional mRNA in the medicine of the future. So buckle up and sit on your hands while the robots and day traders play with the stocks.That was what the priest said to me when I had constipation, you must never stop believing..
- 10 t sittenWill the downturn on wall street put pressure on circio do you think? I don't know how it works with knock on effects etc but I wonder if there will be more turbulence tomorrow because of it? Like we had at the end of today.. Or is there no correlation?Would perhaps be more relevant if there actually was a downturn on wall street. Nasdaq +.022 s&p500 -0.22. Don't quite see what you are talking about
- ·12 t sittenRecovering now in the closing auction 😃Good with patience. What happens to the share price today and tomorrow doesn't matter at all. Rome wasn't built in a day, say those who remember the longest, and no, not rum in a bottle, or room for Romerike (Akershus) 😉
- ·12 t sittenHULTEN shared this earlier, think it needs a bit of top placement now after some people are finished with work! LinkedIn copy Benjamin McLeod ( . Following Founder @ Convey Bio | Co-Host of The Biotech Voyager This is one of the hottest early-stage companies so far this year. The company is Circio Holding ASA They've built a gene expression system that uses circular RNA biogenesis It's seriously impressive: - RNA that last 75x longer than normal - significant reduction in immune response over standard gene delivery highly potent, to the extent that an eye delivery resulted in a 10x response with ONE-TENTH OF THE DOSE Seriously impressive run this year Many thanks to Victor Levitsky for a short overview We barely scratched the surface on all the cool data they've generated Anything else you'd add? Drop it in the comments. https://www.linkedin.com/posts/benjamin-mcleod_this-is-one-of-the-hottest-early-stage-companies-ugcPost-7513474825743437824-HyJM/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7513557495605374976&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUSkreiv dette til han Nice one Benjamin Circio has actually put together a pretty solid data package this year - expression advantage now shown in heart, eye and CNS, first therapeutic gene data, and long durability on the non-viral CAR-T side. Worth a closer look if you haven't dug into the full 2026 progress yet. Fikk svar Definitely need to read deeper Då får vi se om han kommer me noe senere
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 81 | - | - | ||
| 900 | - | - | ||
| 2 000 | - | - | ||
| 5 979 | - | - | ||
| 500 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt